新华制药(000756) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 reached ¥1,825,265,781.44, an increase of 2.03% compared to the same period last year[5] - Net profit attributable to shareholders was ¥122,161,215.07, reflecting a growth of 23.33% year-on-year[5] - Basic earnings per share for Q3 2023 was ¥0.18, up 20.00% year-on-year, while diluted earnings per share also increased by 28.57% to ¥0.18[5] - The net profit attributable to shareholders for the year-to-date period reached RMB 391,968,372.92, representing a year-on-year increase of 33.58%[27] - The operating revenue for the current period was RMB 6,497,534,830.57, compared to RMB 5,453,318,659.20 in the previous period, indicating a growth of approximately 19.06%[35] - The operating profit for the current period was RMB 446,870,220.76, up from RMB 338,081,275.06, marking an increase of about 32.3%[36] - The total comprehensive income for the current period was RMB 424,607,460.38, compared to RMB 281,032,140.69 in the previous period, indicating a significant increase of approximately 51%[36] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥76,245,167.69, a significant decline of 67.39% compared to the previous year, primarily due to prepayments from customers in the prior year[7] - Operating cash inflow for the current period was $5,530,713,748.91, an increase of 17.3% from $4,717,227,178.33 in the previous period[42] - Net cash flow from operating activities decreased to $76,245,167.69, down 67.4% from $233,819,696.10 in the previous period[42] - Cash outflow from financing activities increased to $1,041,449,917.28, compared to $728,570,872.30 in the previous period, reflecting a significant rise of 43%[43] - The company reported a net cash flow from financing activities of -$207,933,462.79, a decline from a positive cash flow of $376,795,259.04 in the previous period[43] - Cash and cash equivalents at the end of the period were $701,723,096.81, down from $1,049,450,512.26, a decrease of 33.2%[43] - Inventory decreased to $970,747,715.80 from $1,211,987,048.39, reflecting a reduction of 19.9%[52] - Total assets at the end of the reporting period were ¥7,921,817,083.48, down 4.15% from the end of the previous year[5] - The company’s total assets decreased from RMB 8,265,131,332.13 to RMB 7,921,817,083.48, a decline of about 4.2%[35] Shareholder and Equity Information - Shareholders' equity attributable to the parent company increased by 8.55% to ¥4,479,374,719.92 compared to the end of the previous year[5] - The total equity attributable to shareholders increased from RMB 4,126,460,390.95 to RMB 4,479,374,719.92, reflecting a growth of approximately 8.5%[35] - The company reported a total of 101,977 common shareholders at the end of the reporting period, with the largest shareholder holding 30.36% of the shares[8] Government Support and Investments - The company received government subsidies amounting to ¥6,357,208.63 during the reporting period, contributing positively to the financial results[5] - The company’s long-term equity investments increased slightly to $58,677,760.60 from $57,154,487.58, showing a growth of 2.7%[52] - The company’s cash inflow from investment activities was $20,162,660.04, up from $16,115,180.00, marking an increase of 25.4%[42] Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[5] - The company continues to focus on expanding its market presence and enhancing profitability through cost reduction and efficiency improvements[27]